Article Versions Notes

Namjoo M, Ghafouri H, Assareh E, Aref AR, Mostafavi E, Hamrahi Mohsen A, Balalaie S, Broussy S, Asghari SM. A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities. Pharmaceuticals. 2023; 16(6):906. https://doi.org/10.3390/ph16060906

Namjoo, Mohadeseh, Hossein Ghafouri, Elham Assareh, Amir Reza Aref, Ebrahim Mostafavi, Ali Hamrahi Mohsen, Saeed Balalaie, Sylvain Broussy, and S. Mohsen Asghari. 2023. "A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities" Pharmaceuticals 16, no. 6: 906. https://doi.org/10.3390/ph16060906

Namjoo, M., Ghafouri, H., Assareh, E., Aref, A. R., Mostafavi, E., Hamrahi Mohsen, A., Balalaie, S., Broussy, S., & Asghari, S. M. (2023). A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities. Pharmaceuticals, 16(6), 906. https://doi.org/10.3390/ph16060906